Source: International Congress 2014 – ILDs 3
Disease area: Interstitial lung diseases

Abstract

Objectives:In a recent safety study we analyzed the effect of inhaled interferon-g (IFN-g) on pulmonary function before and after therapy. We tested the power of our data to predict an endpoint for a controlled clinical trial.Methods:Ten patients with IPF received inhaled IFN-g 100µg 3x/week for 80-130 weeks delivered with I-neb (Philips Respironics). Full PFTs were measured 20-50 weeks before Rx and monthly during Rx. Linear mixed models were used to test the PFT change over time. Autoregressive dependence structure (order one) was the best to model the intra-patient correlation over time. 89 observations were used to build models. PFT with significant changes before and after Rx were used as the primary endpoint to define potential placebo-controlled phase 3 studiesResults:All patients tolerated at least 80 weeks of inhaled IFN-g well, with no systemic side effects. After initiation of inhaled IFN-g, there was a marked change in slope of the DLCO curve from negative to positive indicating an improvement in this parameter. The change over time in DLCO was significantly different before and after interferon treatment (p-value=0.03). Changes in TLC, FRC, RV and FVC were not significant.Power calculations were performed for different sample sizes based on 1000 simulation runs for each sample size. For a sample size of 60, a placebo controlled, randomized trial has a 90% power to detect a significant difference in the change rate of DLCO.Conclusions:Inhaled IFN-g is safe with no systemic side effects in IPF over many months of therapy. DLCO appears to be a sensitive index of response to inhaled IFN-g. As a result of this response, a relatively small sample size for a placebo-controlled trial is possible.

Rating:

Share or cite this content

Citations should be made in the following way:
G. Smaldone, J. Yang, R. Condos (Stony Brook, New York, United States Of America). Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial. Eur Respir J 2014; 44: Suppl. 58, 775

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Mindfulness-based stress reduction in patients with interstitial lung disease: A pilot study Source: International Congress 2014 – ILDs 3 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Live patient and partner survey on pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014